People want peptides, and also clinical oversight.
Awareness. A New Consumer survey found only 41% of Gen Z and millennials say they understand peptides, while another third have heard of them but aren’t sure what they are.
Among Gen X and older adults, awareness drops sharply — just 19% say they understand peptides, while 41% have never heard of them.
Guidance. Younger consumers are the most interested in peptides, but a majority say they’d only take them with clinical guidance, signaling demand for trusted providers over gray-market sourcing.
Performance. Beyond weight loss, early adopters are self-prescribing injections for recovery, muscle growth, and healthy aging, with “Optimizers” almost twice as likely to use research-grade compounds alongside GLP-1s, NAD+, creatine, and wearables.
Access. As regulators weigh broader access, companies from Protocole and Noho Labs to Hims and Noom are racing to legitimize peptide care — integrating clinical guidance, manufacturing, and distribution.
Looking ahead: As biology becomes programmable, digital platforms will plug peptides into DTC infrastructure to accelerate mainstream appeal.
